SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products undergo lengthy regulatory approvals.

Swiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.

Interview with Ian Harrow from the Pistoia Alliance, about how to improve life sciences data management with help of a new digital toolkit that makes data Findable, Accessible, Interoperable, and Reusable – in brief: FAIR.

Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s SVP Global BD Federico Pollano about the CDMO’s expertise in DuoBody® molecules production and the expansion of the CDMO’s U.S. production site in Milford.

According to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked will now go to the € 750 billion rescue fund.

As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.

Germany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec also entered into a comprehensive partnership with the Austrian start-up, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. The Germans will provide hit identification services for Quantro’s proprietary anti-tumour projects.

A biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ in many ways.

An impulse paper of a green splinter group has ignited a storm in the water glass. Like industry and science lobbyists, the renegades are calling for changes to the EU’s legal GMO framework.

BioProfile FLEX2 combines Nova’s groundbreaking MicroSensor Card technology with optical measurement and freezing point osmometry for an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume.